Stai usando un browser molto obsoleto. Puoi incorrere in problemi di visualizzazione di questo e altri siti oltre che in problemi di sicurezza. . Dovresti aggiornarlo oppure usarne uno alternativo, moderno e sicuro.
Obbligazioni societarieHIGH YIELD e oltre, verso frontiere inesplorate - Vol. 1
sarà per la trimestrale non tanto bella, perdon clienti e han pure problemi con le fatturazioni, non ho ben capito come generano il fatturato procapite sui clienti che mi sembra abbastanza alto rispetto alle tariffe, avranno tutti sottoscritto abbonamenti ai canali TV? sti americani senza cable TV non stanno
Valeant Pharmaceuticals International Inc. shares surged 24.10% to close at $12.05 after an upbeat note about its future profits. Valeant said Tuesday its adjusted full-year earnings would be higher than previously anticipated and the company also reported progress in paying down a heavy debt load. Chief Executive Officer Joe Papa has promised to get the company back on stable footing after two very difficult years. Much of Papa’s focus has been on boosting cash flows and paying down some of the $30 billion in debt. Valeant said it had $1.21 billion in cash at the end of the first quarter, more than double what it had at the end of the year. Valeant’s $3.25 billion 5.875% senior unsecured notes due 2023 rallied 2.75 points to 78.875 (10.74% YTW) on heavy volume. The Valeant stack generally was up 2-4 points in active trade.